6 jul 2017 año - The JAMA Viewpoint article by Dr. Scott Gottlieb and Dr. Janet Woodcock entitled, “Marshaling FDA Benefit-Risk Expertise to Address the Current Opioid Abuse Epidemic," was published. Following the FDA’s request, Endo announced that it would voluntarily remove reformulated Opana ER from the market.
Añadido al timeline:
fecha:
6 jul 2017 año
Ahora mismo
~ 8 years and 3 months ago